BioMedNewsBreaks

TuesdayDec 05, 2023 2:45 pm

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Releases Updated Report on Litigation

Safety Shot (NASDAQ: SHOT), makers of the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity, is reporting on its newly filed lawsuit against Capybara Research. According to the update, the company filed a federal lawsuit in the U.S. District Court for the Southern District of New York against Capybara Research on Dec. 4, 2023. In addition, the company is reporting that after weeks of investigatory work by counsel along with third-party assistance and cooperation, the person responsible for the malicious article has been identified. The company is now taking steps…

Continue Reading

MondayDec 04, 2023 3:01 pm

BioMedNewsBreaks – ROTH MKM and Sustain SoCal to Co-Host Upcoming PCE6 Event

ROTH MKM and Sustain Southern California (“Sustain SoCal”) today announced plans to jointly host the 6th Annual Sustainability Private Capital Event (“PCE6”), which will take place in a virtual format on Wednesday, Dec. 6, 2023, and Thursday, Dec. 7, 2023. This year’s conference will feature Company Quick Pitches and 1-on-1 / small group ZOOM meetings, providing investors the opportunity to meet with early-stage sustainability companies in cutting-edge domains, including solar/storage, hydrogen, e-mobility, smart city, circular economy, water and agtech. “The outlook within the sustainability sector remains mixed. The recent passing of the IRA, the IIJA, as well as a series…

Continue Reading

MondayDec 04, 2023 2:53 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is spotlighted in a recent H.C. Wainwright & Co. research report. The report “is initiating coverage on PaxMedica, an emerging firm developing novel formulations of suramin for treatment of neurological disorders with intractable symptoms,” which is “attacking autism with a novel approach.” The report noted that PaxMedica was the first company to design and execute a controlled clinical study based on the agency’s inputs, with top-line data based on retrospective analysis of medical records being presented in November 2023 that “showed PAX-101 (intravenous suramin) clinical meaningfulness in…

Continue Reading

MondayDec 04, 2023 1:59 pm

BioMedNewsBreaks – Safety Shot (NASDAQ: SHOT) Announces Sellout of Product ‘Almost Immediately’ After Being Released on Amazon.com

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, announced that its flagship product, Safety Shot, sold out within hours after being released on Amazon.com. The scientifically formulated beverage is the first patented beverage that helps consumers feel better faster by reducing blood alcohol content and boosting clarity. The announcement noted that the product was released on Amazon on Nov. 30, 2023, and without any introduction or announcement, Safety Shot sold out almost immediately. Amazon is the first direct-to-consumer platform to carry Safety Shot, which can also be purchased from the company’s website; the company also anticipates the product…

Continue Reading

FridayDec 01, 2023 2:59 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Targeting Confirmatory Support for Existing ALS Trial Data with NIH-Funded EAP Study

Clene’s (NASDAQ: CLNN) wholly owned subsidiary Clene Nanomedicine Inc. and its collaborators, Columbia University and Synapticure, recently received a four-year grant totaling $45.1 million. The grant will support an Expanded Access Protocol (“EAP”) study investigating the safety and efficacy of Clene’s investigational product (“IP”), CNM-Au8, as a treatment for people with amyotrophic lateral sclerosis (“ALS”). “CNM-Au8 is an orally administered gold nanocrystal suspension that is thought to improve mitochondrial health and protect neuronal function to treat neurodegenerative diseases. This IP, which clinical studies have shown is well tolerated, can penetrate the blood-brain barrier, stimulate energy production and utilization, and reduce…

Continue Reading

FridayDec 01, 2023 2:10 pm

BioMedNewsBreaks – IBN and BioMedWire Extend Collaboration with Dynamic Global Events

IBN, a comprehensive communications organization with a diverse portfolio of 60+ brands, today announced its fourth consecutive year of collaboration with Dynamic Global Events (“DGE”), a leader in B2B conferences that serve the pharmaceutical and life sciences industries. IBN will serve as an official media partner for the upcoming DGE events in 2024. In addition, BioMedWire (“BMW”), a digital hub within IBN committed to highlighting emerging opportunities in the life sciences industry, will join as an official media partner to further enhance the media coverage of DGE’s events throughout the year. DGE events foster education, networking, business development and partnership…

Continue Reading

FridayDec 01, 2023 1:30 pm

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Eyes ‘Encouraging’ Results from CLEAR MIND Trial

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, in October announced topline results from its phase 2a CLEAR MIND trial, investigating Lomecel-B(TM) for the treatment of mild Alzheimer’s disease (“AD”). “Lomecel-B(TM) is an allogeneic medicinal signaling cell (‘MSC’). MSCs appear to possess anti-inflammatory, pro-vascular and pro-regenerative properties. The study met its primary safety endpoint across all study groups based on statistical and medical assessments, with the safety data consistent with an established safety profile with no incidence of hypersensitivity, no cases of Alzheimer Related Imagine Abnormalities (‘ARIA’), no clinically asymptomatic microhemorrhages, and…

Continue Reading

ThursdayNov 30, 2023 12:32 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Celly Nu Complete Plan of Arrangement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) and Celly Nutrition Corp. (“Celly Nu”) today announced the closing of the previously proposed distribution of a portion of FSD Pharma’s holdings of common shares of Celly Nu (“Celly Nu shares”) to certain securityholders of FSD Pharma through a statutory plan of arrangement under section 182 of the Business Corporations Act (Ontario) (the “plan of arrangement”), per the arrangement agreement dated Oct. 4, 2023. As detailed in FSD Pharma’s press release dated Nov. 21, 2023, the record date of the plan of arrangement was set at Nov. 28, 2023. On Nov. 29,…

Continue Reading

WednesdayNov 29, 2023 2:23 pm

BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering

Tharimmune (NASDAQ: THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory and oncologic conditions, has announced the pricing of an underwritten public offering of 10,000,000 shares of common stock (or pre-funded warrants in lieu thereof). Each share of common stock (or pre-funded warrant) is being sold at a public offering price of $1.00 per share (inclusive of the pre-funded warrant exercise price) for gross proceeds to Tharimmune of $10,000,000. All of the shares of common stock and pre-funded warrants are being offered by the company. In addition, Tharimmune granted the underwriters a 45-day option to…

Continue Reading

WednesdayNov 29, 2023 2:17 pm

BioMedNewsBreaks – Branded Legacy Inc. (BLEG) Commences Buyback of 1M Preferred Class D Shares

Branded Legacy (OTC: BLEG), a pioneer in the biotechnology and wellness industries, announced its strategic decision to buy back and retire 1,000,000 Preferred Class D Shares. The significant move protects against a conversion ratio of 1 Preferred Class D Share to 100 Common Unrestricted shares, marking a pivotal step in enhancing shareholder value and simplifying Branded Legacy’s share structure by preventing these shares from entering the market. “The buyback and retirement of these Preferred Class D Shares is a strategic move to reinforce our shareholders’ value by preventing dilution,” said Branded Legacy CEO David Oswald. “We are committed to enhancing…

Continue Reading